Who Owns Terumo Company?

Terumo Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Terumo Corporation?

Understanding the ownership of a company like Terumo Corporation is crucial for discerning its strategic direction, long-term vision, and accountability to various stakeholders. Company ownership significantly influences decision-making, from investment in research and development to market expansion and corporate governance. A pivotal moment for many companies, such as a major IPO or leadership succession, often reshapes this ownership landscape, impacting its trajectory.

Terumo Corporation, a leading Japanese medical device manufacturer and distributor, was founded on September 17, 1921, as the Red Line Thermometer Corporation. Its founders, a group of medical scientists led by Dr. Shibasaburo Kitasato, envisioned a company that would contribute to society through healthcare by producing essential medical thermometers domestically, especially after imports were disrupted by World War I. Terumo SWOT Analysis can provide further insights into the company's strategic positioning. As of June 13, 2025, Terumo boasts a market capitalization of USD 26.59 billion, making understanding its Terumo ownership structure even more critical for investors and stakeholders alike.

The genesis of the Terumo Corporation, a key player in the medical device industry, dates back to September 17, 1921. It began as the Red Line Thermometer Corporation. The company was founded by a group of medical scientists. They were led by Dr. Shibasaburo Kitasato.

The primary goal of the founders was to manufacture medical thermometers within Japan. This was in response to supply disruptions during World War I. While specific details about the initial equity distribution among the founders are not available in public records, the company's foundation was built on a commitment to healthcare. This commitment was shown through the provision of essential medical devices.

The early ownership structure of the Terumo company focused on establishing a strong manufacturing base for clinical thermometers. Publicly accessible historical records do not provide extensive details about early backers or angel investors. Similarly, information regarding early agreements, such as vesting schedules or founder exits, is not widely available. The founding team's dedication to medical innovation and domestic production was evident in the company's initial product and subsequent expansion.

Early Ownership Insights

The early focus of Terumo was on producing medical thermometers. This was a critical need at the time. The company's early history highlights a commitment to healthcare and domestic production. For more details, you can read Brief History of Terumo.

• The company's early focus was on producing medical thermometers.
• The founding team's commitment to medical innovation was evident.
• Details about early investors are not extensively documented.
• The company's initial product was a clinical thermometer.

Terumo SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The journey of the Terumo Corporation into the public domain began with its Initial Public Offering (IPO) on January 4, 2000. This pivotal move transformed the company's ownership structure, paving the way for broader investor participation and increased market visibility. As of June 13, 2025, the market capitalization of Terumo stands at a robust USD 26.59 billion, reflecting its significant presence in the global medical technology market.

The shift towards public ownership has been a key factor in shaping the company's governance and strategic direction. The evolution of Terumo's ownership structure reflects its growth and adaptation to the dynamics of the global financial markets. This transition has facilitated access to capital and has enhanced its ability to pursue strategic initiatives and expansion opportunities.

The ownership of the Terumo Corporation is largely held by institutional investors, a common characteristic of publicly traded companies. As of March 31, 2023, foreign companies held 33.78% of the issued shares, while trust and banking companies held 39.14%. Other significant shareholders included other financial institutions at 11.59%, other companies at 6.07%, securities companies at 1.90%, and individuals and others at 7.11%. Terumo also held 0.41% in treasury shares on the same date. This distribution underscores the company's integration into the global financial ecosystem. For a deeper understanding of the competitive environment, consider exploring the Competitors Landscape of Terumo.

Key Takeaways on Terumo Ownership

Terumo's ownership structure is dominated by institutional investors, reflecting its status as a publicly traded company.

• The IPO in 2000 marked a significant shift in the company's ownership.
• Major shareholders include Vanguard and MFS, among others.
• The company holds treasury shares, influencing its capital structure.
• The ownership structure impacts corporate governance and strategic decisions.

Terumo PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of May 14, 2025, the leadership of Terumo Corporation includes Toshiaki Takagi, serving as the Representative Director and Chairman of the Board, and Hikaru Samejima as the Representative Director and Chief Executive Officer. Other key figures on the board include Toshihiko Osada, who is a Director and Group Senior Managing Executive Officer, and Norimasa Kunimoto, who holds the position of Director and Group Managing Executive Officer. This structure is designed to guide the strategic direction and operational oversight of the company, ensuring that it meets its objectives and maintains its position in the medical technology market.

The corporate governance structure of Terumo is a Company with an Audit and Supervisory Committee, in compliance with Japan's Companies Act. This framework is designed to strengthen audit and supervisory functions, enhancing transparency and objectivity in management. The Audit and Supervisory Committee members are directors with voting rights in Board of Directors meetings. The majority of the Audit and Supervisory Committee is composed of independent directors, whose opinions are intended to enhance transparency and objectivity by representing the perspective of shareholders and other stakeholders. This structure supports Terumo's commitment to responsible corporate governance and accountability.

The company emphasizes timely decision-making while maintaining transparency and objectivity. To further enhance these aspects, Terumo has established several discretionary bodies, including a Nomination Committee, Remuneration Committee, Corporate Governance Committee, Internal Control Committee, and Risk Management Committee. These committees support the company's efforts to uphold robust corporate governance practices. For a deeper understanding of the company's financial operations, you can explore Revenue Streams & Business Model of Terumo.

Key Takeaways on Terumo's Governance

Terumo's governance structure prioritizes transparency and accountability.

• The Board of Directors includes both executive and independent directors.
• The Audit and Supervisory Committee plays a crucial role in oversight.
• Committees are in place to address nominations, remuneration, and risk.
• The company is committed to shareholder engagement and dialogue.

Terumo Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Terumo's focus has been on strategic investments and internal restructuring. A significant move was the establishment of 'Terumo Ventures' on August 5, 2024, a Corporate Venture Capital (CVC) organization within Terumo Americas Holding. This initiative plans to invest $75 million over the next five years in early-stage companies. This strategic investment in early-stage companies focuses on cardiovascular disease treatment, chronic disease treatment, and digital technologies, aiming to enhance access to innovative technologies and build a robust M&A target pipeline.

From a financial perspective, Terumo reported strong performance for the nine months ending December 31, 2024, with significant year-on-year revenue and profit growth. For the fiscal year ended March 31, 2025, revenue exceeded 1 trillion yen for the first time, reaching JPY 1,036,171 million, a 12.4% increase year-on-year. Operating profit also reached a record high of JPY 157,668 million, up 12.5% year-on-year. Net income and free cash flow also achieved record highs. For fiscal year 2025, management anticipates a 7% revenue growth and 32% operating profit growth on a local currency basis.

Terumo's commitment to shareholder value is evident through its dividend policy. The company aims to steadily increase dividend payouts with a target dividend payout ratio of 30% in the mid to long-term, and a total payout ratio of around 50% during its 5-Year Growth Strategy (GS26). A two-for-one share split was also conducted effective April 1, 2024, impacting earnings per share calculations and cash dividends per share for the fiscal year ending March 2025. Corporate governance has also evolved, with new director appointments and a reorganization of the Board of Directors' supervisory function as of June 26, 2024, and the introduction of a new director position in charge of innovation in April 2024.

Recent Investment

Terumo Ventures, a CVC organization, will invest $75 million over the next five years in early-stage companies. These investments focus on cardiovascular and chronic disease treatments, as well as digital technologies. The initiative aims to enhance access to innovative technologies and build a robust M&A pipeline.

Financial Performance

For the fiscal year ended March 31, 2025, revenue exceeded 1 trillion yen, reaching JPY 1,036,171 million, a 12.4% increase. Operating profit reached a record high of JPY 157,668 million, up 12.5%. The company expects 7% revenue growth and 32% operating profit growth for fiscal year 2025.

Shareholder Value

Terumo aims for a 30% dividend payout ratio in the mid-to-long term and a total payout ratio of around 50% during its 5-Year Growth Strategy. A two-for-one share split was effective April 1, 2024. These actions reflect a commitment to enhancing shareholder value.

Corporate Governance

Terumo has made recent changes including the appointment of new directors and a reorganization of the Board of Directors' supervisory function as of June 26, 2024. A new director position in charge of innovation was also introduced in April 2024, centralizing innovation management.

Terumo Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs